Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Complement System and Antibody-Mediated Transplant Rejection.

Literature DB >> 26637661

The Complement System and Antibody-Mediated Transplant Rejection.

Erik Stites¹, Moglie Le Quintrec², Joshua M Thurman³.

Abstract

Complement activation is an important cause of tissue injury in patients with Ab-mediated rejection (AMR) of transplanted organs. Complement activation triggers a strong inflammatory response, and it also generates tissue-bound and soluble fragments that are clinically useful markers of inflammation. The detection of complement proteins deposited within transplanted tissues has become an indispensible biomarker of AMR, and several assays have recently been developed to measure complement activation by Abs reactive to specific donor HLA expressed within the transplant. Complement inhibitors have entered clinical use and have shown efficacy for the treatment of AMR. New methods of detecting complement activation within transplanted organs will improve our ability to diagnose and monitor AMR, and they will also help guide the use of complement inhibitory drugs.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 26637661 PMCID： PMC4672393 DOI： 10.4049/jimmunol.1501686

Source DB: PubMed Journal: J Immunol ISSN： 0022-1767 Impact factor: 5.422

107 in total

1. Use of C4d as a diagnostic adjunct in lung allograft biopsies.

Authors: Cynthia M Magro; Amy Pope Harman; Dana Klinger; Charles Orosz; Patrick Adams; James Waldman; Deborah Knight; Moira Kelsey; Patrick Ross
Journal: Am J Transplant Date: 2003-09 Impact factor: 8.086

2. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?

Authors: Marta Crespo; Alberto Torio; Virginia Mas; Dolores Redondo; Maria J Pérez-Sáez; Marisa Mir; Anna Faura; Rita Guerra; Olga Montes-Ares; Maria D Checa; Julio Pascual
Journal: Transpl Immunol Date: 2013-07-29 Impact factor: 1.708

3. Complement activation induces the expression of decay-accelerating factor on human mesangial cells.

Authors: T Shibata; F G Cosio; D J Birmingham
Journal: J Immunol Date: 1991-12-01 Impact factor: 5.422

Review 4. Utility of HLA Antibody Testing in Kidney Transplantation.

Authors: Ana Konvalinka; Kathryn Tinckam
Journal: J Am Soc Nephrol Date: 2015-03-24 Impact factor: 10.121

5. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury.

Authors: Walter D Park; Joseph P Grande; Dora Ninova; Karl A Nath; Jeffrey L Platt; James M Gloor; Mark D Stegall
Journal: Am J Transplant Date: 2003-08 Impact factor: 8.086

Review 6. Humoral theory of transplantation.

Authors: Paul I Terasaki
Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086

7. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

Authors: Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov
Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086

8. Complement-binding anti-HLA antibodies and kidney-allograft survival.

Authors: Alexandre Loupy; Carmen Lefaucheur; Dewi Vernerey; Christof Prugger; Jean-Paul Duong van Huyen; Nuala Mooney; Caroline Suberbielle; Véronique Frémeaux-Bacchi; Arnaud Méjean; François Desgrandchamps; Dany Anglicheau; Dominique Nochy; Dominique Charron; Jean-Philippe Empana; Michel Delahousse; Christophe Legendre; Denis Glotz; Gary S Hill; Adriana Zeevi; Xavier Jouven
Journal: N Engl J Med Date: 2013-09-26 Impact factor: 91.245

9. C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack.

Authors: Leendert A Trouw; Anders A Bengtsson; Kyra A Gelderman; Björn Dahlbäck; Gunnar Sturfelt; Anna M Blom
Journal: J Biol Chem Date: 2007-08-15 Impact factor: 5.157

10. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.

Authors: M Haas; B Sis; L C Racusen; K Solez; D Glotz; R B Colvin; M C R Castro; D S R David; E David-Neto; S M Bagnasco; L C Cendales; L D Cornell; A J Demetris; C B Drachenberg; C F Farver; A B Farris; I W Gibson; E Kraus; H Liapis; A Loupy; V Nickeleit; P Randhawa; E R Rodriguez; D Rush; R N Smith; C D Tan; W D Wallace; M Mengel
Journal: Am J Transplant Date: 2014-02 Impact factor: 8.086

29 in total

Review 1. Viral-derived complement inhibitors: current status and potential role in immunomodulation.

Authors: Hadi Abou-El-Hassan; Hassan Zaraket
Journal: Exp Biol Med (Maywood) Date: 2016-10-26

2. Fetal death: an extreme manifestation of maternal anti-fetal rejection.

Authors: Kia Lannaman; Roberto Romero; Tinnakorn Chaiworapongsa; Yeon Mee Kim; Steven J Korzeniewski; Eli Maymon; Nardhy Gomez-Lopez; Bogdan Panaitescu; Sonia S Hassan; Lami Yeo; Bo Hyun Yoon; Chong Jai Kim; Offer Erez
Journal: J Perinat Med Date: 2017-10-26 Impact factor: 1.901

3. Native State of Complement Protein C3d Analysed via Hydrogen Exchange and Conformational Sampling.

Authors: Didier Devaurs; Malvina Papanastasiou; Dinler A Antunes; Jayvee R Abella; Mark Moll; Daniel Ricklin; John D Lambris; Lydia E Kavraki
Journal: Int J Comput Biol Drug Des Date: 2018-03-24

Review 4. Complement in disease: a defence system turning offensive.

Authors: Daniel Ricklin; Edimara S Reis; John D Lambris
Journal: Nat Rev Nephrol Date: 2016-05-23 Impact factor: 28.314

5. Donor apoptotic cell-based therapy for effective inhibition of donor-specific memory T and B cells to promote long-term allograft survival in allosensitized recipients.

Authors: Anil Dangi; Shuangjin Yu; Frances T Lee; Melanie Burnette; Stuart Knechtle; Jean Kwun; Xunrong Luo
Journal: Am J Transplant Date: 2020-04-19 Impact factor: 8.086

6. A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.

Authors: Johann Bartko; Christian Schoergenhofer; Michael Schwameis; Christa Firbas; Martin Beliveau; Colin Chang; Jean-Francois Marier; Darrell Nix; James C Gilbert; Sandip Panicker; Bernd Jilma
Journal: Clin Pharmacol Ther Date: 2018-07-13 Impact factor: 6.875